Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: An association independent of observed disease severity

Clinical and Experimental Dermatology

Volumn 36, Issue 1, 2011, Pages 24-28

  Sato, R ^a   Milligan, G ^b   Molta, C ^a   Singh, A ^a  

^a PFIZER INC   (United States)

^b ADELPHI REAL WORLD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY SURFACE; DISEASE SEVERITY; EUROPE; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE;

ADULT; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 78650094838     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03872.x     Document Type: Article

References (24)

1. Colombo G, Altomare G, Peris K et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008; 4: 559-68.
2. Delfino M Jr, Holt EW, Taylor CR et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008; 59: 439-47.
3. Gelfand JM, Feldman SR, Stern RS et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-8.
4. Schafer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006; 212: 327-37.
5. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511-18.
6. Finzi AF, Mantovani LG, Belisari A. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol 2001; 15: 320-4.
7. Fowler JF, Duh MS, Rovba L et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008; 59: 772-80.
8. Schoffski O, Augustin M, Prinz J et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007; 5: 209-18.
9. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: S57-61.
10. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
12. Horn EJ, Fox KM, Patel V et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963-71.
13. Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245-50.
14. Augustin M, Kruger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72.
15. Heydendael VM, De Borgie CA, Spuls PI et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004; 9: 131-5.
16. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70: 567-71.
17. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
18. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122: 602-7.
19. Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300: 537-44.
20. Anderson P, Benford M, Harris N et al. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin 2008; 24: 3063-72.
21. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-64.
22. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-7.
23. Gelfand JM, Kimball AB, Mostow EN et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11: 400-7.
24. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-10.